Adis Journals
2 files

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Version 2 2019-06-04, 11:34
Version 1 2019-05-22, 15:14
posted on 2019-06-04, 11:34 authored by Irina Proskorovsky, Yun Su, Kyle Fahrbach, Erik Vandendries, Véronique Pagé, Uchenna Onyekwere, Yunyang Wang, Joseph C. Cappelleri, Matthias Stelljes

Full copyright for enhanced digital features is owned by the authors.

Provide enhanced digital features for this article

If you are an author of this publication and would like to provide additional enhanced digital features for your article then please contact

The journal offers a range of additional features designed to increase visibility and readership. All features will be thoroughly peer reviewed to ensure the content is of the highest scientific standard and all features are marked as ‘peer reviewed’ to ensure readers are aware that the content has been reviewed to the same level as the articles they are being presented alongside. Moreover, all sponsorship and disclosure information is included to provide complete transparency and adherence to good publication practices. This ensures that however the content is reached the reader has a full understanding of its origin. No fees are charged for hosting additional open access content.

Other enhanced features include, but are not limited to:
• Slide decks
• Videos and animations
• Audio abstracts
• Audio slides


Pfizer Inc, New York, NY.